OKYO Pharma (OKYO Pharma) EBIT per Share : $-0.16 (TTM As of Mar. 2023)

View and export this data going back to 2022. Start your Free Trial

What is OKYO Pharma EBIT per Share?

OKYO Pharma's EBIT per Share for the six months ended in Mar. 2023 was $-0.16. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.16.

During the past 3 years, the average EBIT per Share Growth Rate was -482.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was -140.80% per year. During the past 10 years, the average EBIT per Share Growth Rate was -31.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for OKYO Pharma's EBIT per Share or its related term are showing as below:

OKYO' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -482.2 Med: 3.9 Max: 60.3
Current: -482.2

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of OKYO Pharma was 60.30% per year. The lowest was -482.20% per year. And the median was 3.90% per year.

OKYO's 3-Year EBIT Growth Rate is ranked worse than
99.92% of 1304 companies
in the Biotechnology industry
Industry Median: 3.6 vs OKYO: -482.20

OKYO Pharma's EBIT for the six months ended in Mar. 2023 was $-8.10 Mil.

OKYO Pharma EBIT per Share Historical Data

The historical data trend for OKYO Pharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OKYO Pharma EBIT per Share Chart

OKYO Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EBIT per Share

Get a 7-Day Free Trial

-0.01

-0.33

-0.01

-0.59

OKYO Pharma Semi-Annual Data
	Sep13	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23
EBIT per Share	Get a 7-Day Free Trial															-0.27	-	-0.17	-	-0.16

OKYO Pharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

OKYO Pharma's EBIT per Share for the fiscal year that ended in Mar. 2023 is calculated as

	EBIT per Share		(A: Mar. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-13.187	/	22.257
=	-0.59

OKYO Pharma's EBIT per Share for the quarter that ended in Mar. 2023 is calculated as

	EBIT per Share		(Q: Mar. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-8.1	/	51.040
=	-0.16

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.16

OKYO Pharma (NAS:OKYO) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

OKYO Pharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of OKYO Pharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

OKYO Pharma (OKYO Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OKYO Pharma Ltd (NAS:OKYO) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

OK10:Germany

Address

14/15 Conduit St, Floor 4, London, GBR, W1S 2XJ

Website

https://www.okyopharma.com

OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.

Executives

John P Brancaccio	director	C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob	director, officer: Chief Executive Officer
Gabriele M Cerrone	director, 10 percent owner, officer: Executive Chairman	265 EAST 66TH STREET, SUITE 16G, NEW YORK NY 10021
Bernard Denoyer	director	C/O CALLISTO PHARMACEUTICALS, INC., 420 LEXINGTON AVENUE, SUITE 1609, NEW YORK NY 10170
Willy Jules Simon	director	PLAYLOGIC INTERNATIONAL NV, CONCERTGEBOUWPLEIN 13, AMSTERDAM P7 1071 LL
Keeren Shah	officer: Chief Financial Officer	55 PARK LANE, LONDON X0 W1K 1NA